The US Bankruptcy Court approved the modified second amended plan of liquidation of INSYS Therapeutics, Inc. on January 16, 2020. The debtor has filed its modified second amended plan in the Court on January 14, 2020. As per the amended plan, the holders of Administrative expense claims of $3.6 million, professional fee claims, priority tax claims of $0.7 million and other priority claims of $0.1 million will either be paid in cash or any other treatment as per the Bankruptcy code. Convenience Class Claims of $2 million shall recover 10%. Secured claims will be paid in full cash or reinstated or any other treatment. Trade and other unsecured claims of $50 million, Insurance related claims of $258 million and Hospital Claims and NAS Monitoring claims of $117 million will be recovered 8.2%. DOJ claims of $283 million will be recovered 5.6%, State Claims and Municipality/ Tribe Claims of $597 million will be recovered 8.3% and Personal injury claims will be paid in cash. 510(a), 510(b), 510(c) subordinated claims and intercompany claims shall be deemed expunged, discharged, released, and extinguished without further action by or order of the Bankruptcy Court. Equity interests shall be deemed surrendered or cancelled. The plan will be funded through cash in hand and assets sales. The Liquidating Trustee will be selected by the mutual agreement of the Creditors’ Committee and the SMT Group Representatives prior to the Confirmation Hearing for distribution of claims.